Impact of age-specific immunity on the timing and burden of the next Zika virus outbreak

by Michel J. Counotte, Christian L. Althaus, Nicola Low, Julien Riou The 2015–2017 epidemics of Zika virus (ZIKV) in the Americas caused widespread infection, followed by protective immunity. The timing and burden of the next Zika virus outbreak remains unclear. We used an agent-based model to simulate the dynamics of age-specific immunity to ZIKV, and predict th e future age-specific risk using data from Managua, Nicaragua. We also investigated the potential impact of a ZIKV vaccine. Assuming lifelong immunity, the risk of a ZIKV outbreak will remain low until 2035 and rise above 50% in 2047. The imbalance in age-specific immunity implies that people in the 15–29 age range will be at highest risk of infection during the next ZIKV outbreak, increasing the expected number of congenital abnormalities. ZIKV vaccine development and licensure are urgent to attain the maximum benefit in reducing the population-level risk of infection and the risk of advers e congenital outcomes. This urgency increases if immunity is not lifelong.
Source: PLoS Neglected Tropical Diseases - Category: Tropical Medicine Authors: Source Type: research

Related Links:

NEW BRUNSWICK, N.J., February 11, 2020 – Johnson &Johnson today announced that its Janssen Pharmaceutical Companies will further expedite its investigational coronavirus vaccine program through an expanded collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health &Human Services. The collaborative partnership with BARDA builds on Johnson &Johnson’s multipronged response to the new coronavirus disease (COVID-19) outbreak. In addition to Janssen’s effor...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
Pandemics are perversely democratic. They’re nasty, lethal and sneaky, but they don’t discriminate. No matter your age, ethnicity, religion, gender, or nation, you’re a part of the pathogenic constituency. That shared vulnerability, and the resulting human collectivism—a universal response to a universal threat—is newly and vividly evident in the face of the now-global outbreak of the novel coronavirus known as 2019-nCoV. As of writing, there have been over 30,000 diagnosed cases and over 630 related deaths. A virus that emerged in a single city, Wuhan, China—indeed, in a single crowded ...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized 2019-nCoV Infectious Disease Source Type: news
“Everyone knows that pestilences have a way of recurring in the world,” observes Albert Camus in his novel The Plague. “Yet somehow we find it hard to believe in ones that crash down on our heads from a blue sky. There have been as many plagues as wars in history; yet plagues and wars always take people by surprise.” Camus was imagining a fictional outbreak of plague in 1948 in Oran, a port city in northwest Algeria. But at a time when the world is reeling from a very real microbial emergency sparked by the emergence of a novel coronavirus in Wuhan, central China, his observations are as pertinent a...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized 2019-nCoV health ideas Source Type: news
While the threat of the new coronavirus in the United States remains limited, a network of U.S. government agencies are already furiously ramping up efforts to contain the disease, should an outbreak occur. “We are working to keep the risk low,” said Health and Human Services Secretary Alex Azar, who is leading the federal government’s response, at a press conference Friday. So far, the overwhelming number of new cases of the virus, which originated in Wuhan, China, remain in China. There are only 11 confirmed cases in the U.S. The good news, some officials and infectious disease experts tell TIME, is t...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Source Type: news
The TWiVerers continue their coverage of the new coronavirus outbreak in China, as the number of cases increase dramatically and the virus begins person-to-person transmission in other countries. Hosts: Vincent Racaniello, Dickson Despommier, Alan Dove, Rich Condit, Kathy Spindler, and Brianne Barker Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode ASV 2020 Real time tracking of 2019-nCoV (JHU) Estimation of 2019-nCoV R0 (Int J Inf Dis) WHO Sitreps on 2019-nCoV Coronavirus overtakes SARS (SCMP) HHS press conference Discovery of 201...
Source: This Week in Virology - MP3 Edition - Category: Virology Authors: Source Type: podcasts
Abstract Zika Virus (ZIKV) is a Flavivirus transmitted primarily via the bite of infected Aedes aegypti mosquitoes. Globally, 87 countries and territories have recorded autochthonous mosquito-borne transmission of ZIKV as at July 2019 and distributed across four of the six WHO Regions. Outbreaks of ZIKV infection peaked in 2016 and declined substantially throughout 2017 and 2018 in the Americas region. There is the likely risk for ZIKV to spread to more countries. There is also the potential for the re-emergence of ZIKV in all places with prior reports of the virus transmission. The current status of ZIKV transmis...
Source: Virology - Category: Virology Authors: Tags: Virology Source Type: research
NEW BRUNSWICK, N.J., January 29, 2020 – Johnson &Johnson today announced that it is mobilizing resources at its Janssen Pharmaceutical Companies to launch a multi-pronged response to the novel coronavirus (also known as 2019-nCoV or Wuhan coronavirus) outbreak. As part of this work, the Company has initiated efforts to develop a vaccine candidate against 2019-nCoV and broadly collaborate with others to screen a library of antiviral therapies. Identifying compounds with antiviral activity against 2019-nCoV may contribute to providing immediate relief to the current outbreak.“J&J has a long-standing commitmen...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Our Company Source Type: news
Abstract In recent years, the Zika virus has emerged from a neglected flavivirus to a health-threatening pathogen that causes epidemic outbreaks associated with neurological disorders and congenital malformations. In addition to vaccine development, the discovery of specific antiviral agents has been pursued intensely. The Zika virus protease NS2B-NS3 catalyses the processing of the viral precursor polyprotein as an essential step during viral replication. Since the epidemic Zika virus outbreak in the Americas, several inhibitors of this protease have been reported. Substrate-derived peptides revealed important st...
Source: Bioorganic and Medicinal Chemistry Letters - Category: Chemistry Authors: Tags: Bioorg Med Chem Lett Source Type: research
AbstractHuman challenge trials (HCTs) deliberately infect participants in order to test vaccines and treatments in a controlled setting, rather than enrolling individuals with natural exposure to a disease. HCTs are therefore potentially powerful tools to prepare for future outbreaks of emerging infectious diseases. Yet when an infectious disease is emerging, there is often substantial risk and uncertainty about its complications, and few available interventions, making an HCT ethically complex. In light of the need to consider ethical issues proactively as a part of epidemic preparedness, we use the case of a Zika virus H...
Source: Trials - Category: Research Source Type: clinical trials
her For the first 60 years following its isolation, Zika virus (ZIKV) remained a relatively poorly described member of the Flaviviridae family. However, since 2007, it has caused a series of increasingly severe outbreaks and is now associated with neurological symptoms such as Guillain-Barré syndrome and congenital Zika syndrome (CZS). A number of reports have improved our understanding of rare complications that may be associated with ZIKV infection in adults, the areas of the body to which it spreads, and viral persistence in various tissues. Likewise, studies on the effect of ZIKV infection during pregnan...
Source: Viruses - Category: Virology Authors: Tags: Review Source Type: research
More News: Epidemics | Epidemiology | Nicaragua Health | Outbreaks | Tropical Medicine | Vaccines | Zika Virus